Marie-Claude Jacques appointed Senior Vice President, Global Sales; Antwan Gipson joins as Senior Vice President, Manufacturing & Operations
Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Sean...
Continued Momentum Toward PMA Submission of ULTC Technologies Recent Financing Positions Company to Execute Growth Strategy
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management...
Proceeds Expected to Fund Ongoing Development and Submission Activities to Support FDA Evaluation of Company’s First and Next Generation Proprietary Ultralow Cryoablation Technologies
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update...
Financing to Provide Approximately $19 Million in Upfront Proceeds
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...
97% Acute Effectiveness and Favorable Safety Results from Proprietary ULTC for Ventricular Tachycardia
Study Results are Intended to Support PMA Approval of Adagio’s vCLAS TM Cryoablation System Designed to Address the Large Population of Patients with Ventricular Arrhythmias